The Otsuka Patient Assistance Foundation makes very large, narrowly focused grants that fund direct patient assistance to provide pharmaceutical products free of charge to eligible individuals. Nearly all recorded giving is concentrated in a single program delivering medication access/affordability, suggesting the foundation’s primary mission is to ensure patients obtain prescribed medicines rather than broad-based nonprofit support. Nonprofits that operate or partner with patient assistance programs, pharmaceutical access initiatives, or help patients navigate medication affordability are the most likely fit. Giving is highly concentrated (few grants, very large dollar amounts) and operationally focused on distributing medications to patients.
Very large, concentrated grants to a single program/recipient (few grants funding a centralized patient assistance program)
Notable grantees: Individual Patient Programs (patient assistance providing free pharmaceutical products)
Otsuka Patient Assistance Foundation Inc makes its largest recorded grants to a single purpose: providing pharmaceutical products free of charge to eligible patients. The foundation’s recent filings show a tightly focused pattern of support for Individual Patient Programs in Princeton, with each recorded award directed to medication access rather than broad nonprofit programming. In 2025, it granted $351,039,575 to Individual Patient Programs for providing pharmaceutical products free of charge to eligible patients. That followed a $279,656,091 grant in 2024 and a $218,551,062 grant in 2023, all tied to the same purpose. This is not a diversified grantmaker with many thematic strands; the grant history points to an operational model built around prescription support and direct patient assistance. For nonprofit researchers, the key takeaway is that the foundation’s work is centered on helping eligible patients obtain prescribed medicines through a repeated, program-specific funding structure.
The foundation’s giving is concentrated in medication access and prescription assistance. In 2025, it awarded $351,039,575 to Individual Patient Programs for providing pharmaceutical products free of charge to eligible patients, showing a direct-service approach to affordability. The same purpose appears in the 2024 grant of $279,656,091 and the 2023 grant of $218,551,062, reinforcing a consistent patient-assistance model rather than a rotating set of causes. Its recent grants also point to pharmaceutical supply distribution as the core activity being supported, with funding tied to getting products to eligible patients. Across the available record, the cause area is narrow and operational: prescription drugs, patient access, and cost-offset support through a named patient program.
The recorded grant sizes are extremely large and tightly clustered: p25 is $233,827,319, median is $249,103,576, and p75 is $264,379,834. The recent grant record shows repeated awards over multiple years to the same recipient program, indicating a recurring relationship rather than one-off philanthropy. The foundation is a regular funder, not a DAF, and it does not make program-related investments. The pattern is consistent with a direct patient-assistance model, with funding structured around distribution of pharmaceutical products free of charge to eligible patients.
$351M
$72.2M
$401.9M
$361.4M
Most grants fall between $233.8M and $264.4M, with a median of $249.1M.
25th Percentile
$233.8M
Median
$249.1M
75th Percentile
$264.4M
About 100% of grants go to recipients in NJ.
Sign up for a free Kindora account to access AI-generated insights into this funder's giving patterns, decision-makers, and fit signals.
Get Started FreeFree Kindora accounts unlock side-by-side comparisons with foundations that share this funder's focus areas and giving profile.
Get Started FreeRegístrate gratis para ver qué tan bien se adapta tu organización sin fines de lucro a este financiador, obtener un pitch generado por IA y descubrir fundaciones similares.
Grant activity is highly localized. All recorded grants in the provided data went to recipients in New Jersey, and the top state by grant count is NJ with 100% of grants going to recipients in the HQ state. The recent grants list places the recipient program in Princeton, NJ. No non-U.S. recipient countries appear in the data.
Its recorded grants support Individual Patient Programs that provide pharmaceutical products free of charge to eligible patients. The recent grant record ties each of the three listed awards to medication access and prescription support rather than general nonprofit programming.
The grant-size distribution is extremely high: p25 is $233,827,319, the median is $249,103,576, and p75 is $264,379,834. The recent record also includes a 2025 award of $351,039,575.
Yes. The same recipient program appears in 2025, 2024, and 2023, each time for the same purpose of providing pharmaceutical products free of charge to eligible patients. That pattern shows a continuing relationship over multiple years.
All recorded grants in the provided data go to recipients in New Jersey. The recipient program listed in the recent grants table is in Princeton, NJ, and the grant-country distribution is entirely U.S.-based.
2025
Source: IRS Form 990-PF, fiscal year 2025.
Most recent grants reported to the IRS.
| Recipient | Location | Amount | Year | Purpose |
|---|---|---|---|---|
| INDIVIDUAL PATIENT PROGRAMS | PRINCETON, NJ | $351,039,575 | 2025 | PROVIDING PHARMACEUTICAL PRODUCTS FREE OF CHARGE TO ELIGIBLE PATIENTS |
| INDIVIDUAL PATIENT PROGRAMS | PRINCETON, NJ | $279,656,091 | 2024 | PROVIDING PHARMACEUTICAL PRODUCTS FREE OF CHARGE TO ELIGIBLE PATIENTS |
| INDIVIDUAL PATIENT PROGRAMS | PRINCETON, NJ | $218,551,062 | 2023 | PROVIDING PHARMACEUTICAL PRODUCTS FREE OF CHARGE TO ELIGIBLE PATIENTS |
INDIVIDUAL PATIENT PROGRAMS
$351,039,575PROVIDING PHARMACEUTICAL PRODUCTS FREE OF CHARGE TO ELIGIBLE PATIENTS
INDIVIDUAL PATIENT PROGRAMS
$279,656,091PROVIDING PHARMACEUTICAL PRODUCTS FREE OF CHARGE TO ELIGIBLE PATIENTS
INDIVIDUAL PATIENT PROGRAMS
$218,551,062PROVIDING PHARMACEUTICAL PRODUCTS FREE OF CHARGE TO ELIGIBLE PATIENTS